Published in

Public Library of Science, PLoS ONE, 7(10), p. e0132430, 2015

DOI: 10.1371/journal.pone.0132430

Links

Tools

Export citation

Search in Google Scholar

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

Journal article published in 2015 by Steven F. L. Van lelyveld, Julia Drylewicz, Krikke 1☯, Maaike Krikke, Ellen M. Veel, Sigrid A. Otto, Clemens Richter, Robin Soetekouw, Jan M. Prins ORCID, Kees Brinkman, Jan Willem Mulder, Frank Kroon, Ananja Middel, Jori Symons, Annemarie M. J. Wensing and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Objective The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled trial to determine the effect of maraviroc intensification on CD4 + T-cell counts and immune activation in these patients. Design Double-blind, placebo-controlled, randomized trial. Methods Major inclusion criteria were 1. CD4 + T-cell count <350 cells/μL while at least two years on cART or CD4 + T-cell count <200 cells/μL while at least one year on cART, and 2. viral suppression for at least the previous 6 months. HIV-infected patients were randomized to add maraviroc (41 patients) or placebo (44 patients) to their cART regimen for 48 weeks.